Swiss National Bank Sells 4,500 Shares of Repligen Co. (NASDAQ:RGEN)

Swiss National Bank trimmed its stake in Repligen Co. (NASDAQ:RGEN) by 2.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 165,600 shares of the biotechnology company’s stock after selling 4,500 shares during the period. Swiss National Bank owned about 0.30% of Repligen worth $29,775,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Signaturefd LLC grew its position in Repligen by 44.1% in the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 86 shares during the period. Milestone Investment Advisors LLC acquired a new position in Repligen in the third quarter worth $61,000. Headlands Technologies LLC acquired a new position in Repligen in the third quarter worth $75,000. Nisa Investment Advisors LLC boosted its stake in Repligen by 67.6% in the third quarter. Nisa Investment Advisors LLC now owns 533 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 215 shares in the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC acquired a new position in Repligen in the third quarter worth $95,000. 97.64% of the stock is currently owned by institutional investors.

Repligen Stock Down 1.3 %

NASDAQ:RGEN opened at $165.50 on Thursday. The stock has a market cap of $9.25 billion, a price-to-earnings ratio of 662.00, a PEG ratio of 5.58 and a beta of 1.03. The company has a current ratio of 6.35, a quick ratio of 5.24 and a debt-to-equity ratio of 0.26. The stock has a 50-day moving average price of $179.23 and a two-hundred day moving average price of $174.56. Repligen Co. has a 1 year low of $110.45 and a 1 year high of $211.13.

Repligen (NASDAQ:RGEN) last announced its earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.01). Repligen had a return on equity of 3.95% and a net margin of 2.44%. The company had revenue of $151.31 million for the quarter, compared to analyst estimates of $150.06 million. During the same quarter last year, the business posted $0.64 earnings per share. The business’s quarterly revenue was down 17.1% on a year-over-year basis. As a group, equities analysts expect that Repligen Co. will post 1.46 earnings per share for the current year.

Insider Activity

In related news, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the sale, the chief executive officer now owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $193.73, for a total transaction of $681,348.41. Following the sale, the vice president now directly owns 24,260 shares of the company’s stock, valued at $4,699,889.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Anthony Hunt sold 16,707 shares of the company’s stock in a transaction on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the sale, the chief executive officer now directly owns 185,249 shares in the company, valued at $36,575,562.56. The disclosure for this sale can be found here. Insiders have sold a total of 25,597 shares of company stock worth $5,039,532 over the last three months. Corporate insiders own 1.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on RGEN shares. Stifel Nicolaus boosted their price objective on Repligen from $165.00 to $207.00 and gave the stock a “buy” rating in a research note on Thursday, February 22nd. KeyCorp upped their price target on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. Finally, JPMorgan Chase & Co. cut their price target on Repligen from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Thursday, May 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and an average target price of $197.75.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.